| Assessment Status | Rapid Review Complete |
| HTA ID | 23008 |
| Drug | House dust mite allergen extract |
| Brand | Actair® |
| Indication | Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults. |
| Assessment Process | |
| Rapid review commissioned | 10/02/2023 |
| Rapid review completed | 24/02/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM allergen extracts compared with the current standard of care. |
| Full HTA commissioned by the HSE | 01/03/2023 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.